Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk

[News]

An individualized neoantigen mRNA vaccine was tested in patients with early-stage triple-negative breast cancer and showed feasibility, safety, and strong T cell immune responses. Long-term follow-up suggested durable immune memory with encouraging relapse-free outcomes, though controlled trials are needed to confirm clinical benefit.

More... (https://www.news-medical.net/news/20260219/Precision-mRNA-vaccine-strategy-shows-early-promise-for-improving-TNBC-relapse-risk.aspx)